South and Central America Next-generation Antibody Market Forecast to 2028 - COVID-19 Impact and Regional Analysis By Therapeutic Area (Oncology, and Autoimmune or Inflammatory) and Technology (Antibody-drug conjugates, Bispecific antibodies, Fc engineered antibodies, Antibody fragments & antibody-like proteins, and Biosimilar antibody products)
The South and Central America (SCAM) next-generation antibody market are expected to reach US$ 695.60 million by 2028 from US$ 333.92 million in 2021. It is estimated to grow at a CAGR of 1% from 2021 to 2028.
The growth of the market is due to are increasing prevalence of cancer and growing demand for next-generation antibody therapeutics. However, complications associated with the manufacturing and approvals of next-generation antibodies is expected to restrict the market growth during the forecast period.
Continuous medical science improvements and research & developments extend longevity and improve quality of life. Next-generation antibodies are majorly designed to treat various types of cancer. At the same time, new candidates are also being explored for other indications such as infectious diseases and central nervous system disorders. According to Genentech's Senior Vice President of Research Biology, next-generation antibodies have the potential to treat every condition. In addition, the Catalent Biologics Vice President and General Manager believe that the new modalities being incorporated into next-generation antibodies not only offer improved performance over their monoclonal counterparts but also help in offering the potential for new mechanisms of action, allowing access to multiple targets and multiple targeting within the same molecule.
Market players are innovating and advancing their technology to develop new products and therapies using next-generation antibodies and conjugates. For instance, in October 2021, Merck, a leading science and technology company, announced the launch of new technology and expanded the capacity of its Life Science business to produce advanced next-generation Antibody-Drug Conjugate (ADC) therapies. These initiatives underscore Merck's continued investment in novel modalities and support its efforts to double its ADC and high-potent active pharmaceutical ingredient (HPAPI) capacity in the near future. Additionally, in clinical trials, antibody therapies are increasingly being studied and approved, with over 570 therapies in various clinical stages, including 62 in late-stage clinical trials. Therefore, the developments mentioned above would result in significant trends in the next-generation antibody market during the forecast period.
South and Central America witnessed a massive number of COVID-19 cases. The increasing number of cases in Brazil, Peru, Chile, Ecuador, and Venezuela is expected to impact the market over the forecast period negatively.
A considerable number of countries in South America have very underdeveloped healthcare infrastructure. For instance, Peru has less than 1000 intensive care unit beds for its 32 million inhabitants. Furthermore, supply chain disruption caused due to congestion of ports and disturbances in other transport means had a substantial impact on the distribution of associated devices in the region. These factors are currently aiding the SCAM next-generation antibody market and are projected to continue supporting it over the forecast period.
South and Central America Next-generation Antibody Market Revenue and Forecast to 2028 (US$ Mn)
Get more information on this report :
SOUTH AND CENTRAL AMERICA NEXT-GENERATION ANTIBODY MARKET SEGMENTATION
By Therapeutic Area
- Oncology
- Autoimmune/Inflammatory
By Technology
- Antibody-Drug Conjugates (ADC's)
- Bispecific Antibodies
- FC Engineered Antibodies
- Antibody Fragments and Antibody-like Proteins
- Biosimilar Antibody Products
By Country
- Brazil
- Argentina
- Rest of South and Central America
Company Profiles
- F. HOFFMANN-LA ROCHE LTD.
- Takeda Pharmaceutical Company Limited
- Pfizer Inc.
- Catalent Inc
- AstraZenec
1. Introduction
1.1 Study Scope
1.2 The Insight Partners Research Report Guidance
1.3 Market Segmentation
1.3.1 South and Central America Next-generation Antibody Market – By Therapeutic Area
1.3.2 South and Central America Next-generation Antibody Market – By Technology
1.3.3 South and Central America Next-generation Antibody Market – By Country
2. Key Takeaways
3. Research Methodology
3.1 Coverage
3.2 Secondary Research
3.3 Primary Research
4. Next-generation Antibody Market – Market Landscape
4.1 Overview
4.2 PEST Analysis
4.2.1 South and Central America PEST Analysis
4.3 Experts Opinion
5. Next-generation Antibody Market – Key Market Dynamics
5.1 Market Drivers
5.1.1 Increasing Prevalence of Cancer
5.1.2 Growing Demand for Next-Generation Antibody Therapeutics
5.2 Market Restraints
5.2.1 Complications Associated with Manufacturing and Approvals
5.3 Market Opportunities
5.3.1 Proliferation of Biotechnology Industry in Developing Regions
5.4 Future Trends
5.4.1 Developments in Next-Generation Antibodies
5.5 Impact Analysis
6. Next-generation Antibody Market– South and Central America Analysis
6.1 South and Central America Next-generation Antibody Market Revenue Forecast and Analysis
7. South and Central America Next-generation Antibody Market Revenue and Forecasts To 2028– by Therapeutic Area
7.1 Overview
7.2 South and Central America Next-generation Antibody Market, By Therapeutic Area, 2021 & 2028 (%)
7.3 Oncology
7.3.1 Overview
7.3.2 Oncology: Next-generation Antibody Market Revenue and Forecasts to 2028 (US$ Million)
7.4 Autoimmune or Inflammatory
7.4.1 Overview
7.4.2 Autoimmune or Inflammatory: Next-generation Antibody Market Revenue and Forecasts to 2028 (US$ Million)
8. South and Central America Next-generation Antibody Market Revenue and Forecasts To 2028 – Technology
8.1 Overview
8.2 South and Central America Next-generation Antibody Market Share by Segment - 2021 & 2028 (%)
8.3 Antibody-drug conjugates
8.3.1 Overview
8.3.2 Antibody-drug conjugates: Next-generation Antibody Market Revenue and Forecast to 2028 (US$ Million)
8.4 Bispecific antibodies
8.4.1 Overview
8.4.2 Bispecific antibodies: Next-generation Antibody Market Revenue and Forecast to 2028 (US$ Million)
8.5 Fc engineered antibodies
8.5.1 Overview
8.5.2 Fc engineered antibodies: Next-generation Antibody Market Revenue and Forecast to 2028 (US$ Million)
8.6 Antibody fragments and antibody-like proteins
8.6.1 Overview
8.6.2 Antibody fragments and antibody-like proteins: Next-generation Antibody Market Revenue and Forecast to 2028 (US$ Million)
8.7 Biosimilar antibody products
8.7.1 Overview
8.7.2 Biosimilar antibody products: Next-generation Antibody Market Revenue and Forecast to 2028 (US$ Million)
9. South and Central America Next-generation Antibody Market Revenue and Forecasts to 2028 –Country Analysis
9.1 South and Central America Next-generation Antibody Market Revenue and Forecasts To 2028
9.1.1 Overview
9.1.2 South and Central America: Next-generation Antibody Market – Revenue and Forecast to 2028 (US$ Million)
9.1.3 South and Central America: Next-generation Antibody Market, by Therapeutic Area, 2019–2028 (US$ Million)
9.1.4 South and Central America: Next-generation Antibody Market, by Technology, 2019–2028 (US$ Million)
9.1.5 South and Central America: Next-generation Antibody Market, by Country, 2021 & 2028 (%)
9.1.5.1 Brazil: Next-generation Antibody Market – Revenue and Forecast to 2028 (US$ Million)
9.1.5.1.1 Overview
9.1.5.1.2 Brazil: Next-generation Antibody Market – Revenue and Forecast to 2028 (US$ Million)
9.1.5.1.3 Brazil: Next-generation Antibody Market, by Therapeutic Area, 2019–2028 (US$ Million)
9.1.5.1.4 Brazil: Next-generation Antibody Market, by Technology, 2019–2028 (US$ Million)
9.1.5.2 Argentina: Next-generation Antibody Market – Revenue and Forecast to 2028 (US$ Million)
9.1.5.2.1 Overview
9.1.5.2.2 Argentina: Next-generation Antibody Market – Revenue and Forecast to 2028 (US$ Million)
9.1.5.2.3 Argentina: Next-generation Antibody Market, by Therapeutic Area, 2019–2028 (US$ Million)
9.1.5.2.4 Argentina: Next-generation Antibody Market, by Technology, 2019–2028 (US$ Million)
9.1.5.3 Rest of South & Central America: Next-generation Antibody Market – Revenue and Forecast to 2028 (US$ Million)
9.1.5.3.1 Overview
9.1.5.3.2 Rest of South & Central America: Next-generation Antibody Market – Revenue and Forecast to 2028 (US$ Million)
9.1.5.3.3 Rest of South & Central America: Next-generation Antibody Market, by Therapeutic Area, 2019–2028 (US$ Million)
9.1.5.3.4 Rest of South & Central America: Next-generation Antibody Market, by Technology, 2019–2028 (US$ Million)
10. Impact Of COVID-19 Pandemic on Next-generation Antibody Market
10.1 South and Central America: Impact Assessment of COVID-19 Pandemic
11. Next-generation Antibody Market–Industry Landscape
11.1 Overview
11.2 Organic Developments
11.2.1 Overview
11.3 Inorganic Developments
11.3.1 Overview
12. Company Profiles
12.1 F. HOFFMANN-LA ROCHE LTD.
12.1.1 Key Facts
12.1.2 Business Description
12.1.3 Products and Services
12.1.4 Financial Overview
12.1.5 SWOT Analysis
12.1.6 Key Developments
12.2 Amgen Inc.
12.2.1 Key Facts
12.2.2 Business Description
12.2.3 Products and Services
12.2.4 Financial Overview
12.2.5 SWOT Analysis
12.2.6 Key Developments
12.3 Pfizer Inc.
12.3.1 Key Facts
12.3.2 Business Description
12.3.3 Products and Services
12.3.4 Financial Overview
12.3.5 SWOT Analysis
12.3.6 Key Developments
12.4 Catalent Inc
12.4.1 Key Facts
12.4.2 Business Description
12.4.3 Products and Services
12.4.4 Financial Overview
12.4.5 SWOT Analysis
12.4.6 Key Developments
12.5 AstraZeneca
12.5.1 Key Facts
12.5.2 Business Description
12.5.3 Products and Services
12.5.4 Financial Overview
12.5.5 SWOT Analysis
12.5.6 Key Developments
13. Appendix
13.1 About The Insight Partners
13.2 Glossary of Terms
LIST OF TABLES
Table 1. New Cancer Cases Registered Worldwide, 2020
Table 2. South and Central America: Next-generation Antibody Market, by Therapeutic Area – Revenue and Forecast to 2028 (US$ Million)
Table 3. South and Central America: Next-generation Antibody Market, by Technology – Revenue and Forecast to 2028 (US$ Million)
Table 4. Brazil: Next-generation Antibody Market, by Therapeutic Area – Revenue and Forecast to 2028 (US$ Million)
Table 5. Brazil: Next-generation Antibody Market, by Technology – Revenue and Forecast to 2028 (US$ Million)
Table 6. Argentina: Next-generation Antibody Market, by Therapeutic Area – Revenue and Forecast to 2028 (US$ Million)
Table 7. Argentina: Next-generation Antibody Market, by Technology – Revenue and Forecast to 2028 (US$ Million)
Table 8. Rest of South & Central America: Next-generation Antibody Market, by Therapeutic Area – Revenue and Forecast to 2028 (US$ Million)
Table 9. Rest of South & Central America: Next-generation Antibody Market, by Technology – Revenue and Forecast to 2028 (US$ Million)
Table 10. Organic Developments in the Next-generation Antibody Market
Table 11. Inorganic Developments in the Next-generation Antibody Market
Table 12. Glossary of Terms
LIST OF FIGURES
Figure 1. Next-generation Antibody Market Segmentation
Figure 2. Next-generation Antibody Market, By Country
Figure 3. South and Central America Next-generation Antibody Market Overview
Figure 4. Oncology Segment Held Largest Share of Therapeutic Area Segment in Next-generation Antibody Market
Figure 5. South and Central America Next-generation Antibody Market- Leading Country Markets (US$ Million)
Figure 6. South And Central America: PEST Analysis
Figure 7. Experts Opinion
Figure 8. Next-Generation Antibody Market Impact Analysis of Driver and Restraints
Figure 9. South and Central America Next-generation Antibody Market– Revenue Forecast and Analysis – 2021 - 2028
Figure 10. South and Central America Next-generation Antibody Market, by Therapeutic Area, 2021 & 2028 (%)
Figure 11. Oncology: Next-generation Antibody Market Revenue and Forecasts to 2028 (US$ Million)
Figure 12. Autoimmune or Inflammatory: Next-generation Antibody Market Revenue and Forecasts to 2028 (US$ Million)
Figure 13. South and Central America Next-generation Antibody Market Share by Segment - 2021 & 2028 (%)
Figure 14. Antibody-drug conjugates: Next-generation Antibody Market Revenue and Forecasts To 2028 (US$ Million)
Figure 15. Bispecific antibodies: Next-generation Antibody Market Revenue and Forecasts To 2028 (US$ Million)
Figure 16. Fc engineered antibodies: Next-generation Antibody Market Revenue and Forecasts To 2028 (US$ Million)
Figure 17. Antibody fragments and antibody-like proteins: Next-generation Antibody Market Revenue and Forecasts To 2028 (US$ Million)
Figure 18. Biosimilar antibody products: Next-generation Antibody Market Revenue and Forecasts To 2028 (US$ Million)
Figure 19. South and Central America: Next-generation Antibody Market, by Key Country – Revenue (2021) (US$ Million)
Figure 20. South and Central America Next-generation Antibody Market Revenue and Forecast to 2028 (US$ Million)
Figure 21. South and Central America: Next-generation Antibody Market, by Country, 2021 & 2028 (%)
Figure 22. Brazil: Next-generation Antibody Market – Revenue and Forecast to 2028 (US$ Million)
Figure 23. Argentina: Next-generation Antibody Market – Revenue and Forecast to 2028 (US$ Million)
Figure 24. Rest of South & Central America: Next-generation Antibody Market – Revenue and Forecast to 2028 (US$ Million)
Figure 25. Impact of COVID-19 Pandemic in South and Central American Countries
- F. HOFFMANN-LA ROCHE LTD.
- Takeda Pharmaceutical Company Limited
- Pfizer Inc.
- Catalent Inc
- AstraZeneca
- Save and reduce time carrying out entry-level research by identifying the growth, size, leading players and segments in the South and Central America next-generation antibody market.
- Highlights key business priorities in order to assist companies to realign their business strategies.
- The key findings and recommendations highlight crucial progressive industry trends in the South and Central America next-generation antibody market, thereby allowing players across the value chain to develop effective long-term strategies.
- Develop/modify business expansion plans by using substantial growth offering developed and emerging markets.
- Scrutinize in-depth market trends and outlook coupled with the factors driving the market, as well as those hindering it.
- Enhance the decision-making process by understanding the strategies that underpin security interest with respect to client products, segmentation, pricing and distribution.